---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-016922"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T04:57:41.407831+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Pieris discontinues respiratory collaboration with Genentech for scientific reasons

## Summary
- Pieris and Genentech jointly ended the respiratory program in May 2023.
- Program aimed at locally delivered respiratory therapies using Pieris' Anticalin technology.
- Discontinuation attributed to scientific reasons; no financial terms disclosed.
- Pieris furnished a June 2023 investor presentation (Exhibit 99.1) with no updated guidance.

## SEC filing metadata
- accession: 0001437749-23-016922
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774923016922/0001437749-23-016922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774923016922/pirs20230601_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-016922
- JSON: https://secwatch.observer/filing/0001437749-23-016922.json
- Plain text: https://secwatch.observer/filing/0001437749-23-016922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.